Sign up for ICER's Weekly View Newsletter

Programming note: Weekly View will be back in your inbox on July 24th!

 

Weekly View


July 10, 2026

From the desk of Priya Ranade

Good morning, everyone.

From ICER’s President and CEO, Sarah K. Emond, MPP:


Like many of you, I have spent some time reflecting this 4th of July as America celebrates its 250th birthday. I’ve been thinking about the promise of this great experiment, especially in terms of health innovation. The American health care system has produced some of the world’s most incredible innovations, from mass production of penicillin to polio vaccination to the sequencing of the human genome. But increasingly patients are challenged to access what our innovation ecosystem is producing because of costs, misaligned incentives, and the opaqueness of the status quo.

 

At ICER, we have always believed that innovations should be priced based on how much value they provide to patients. Given this incredible moment, we are proud to be one of the organizations that is pushing America to better meet the promise of affordable access. ICER strives to bring research about pricing and access of health interventions out in the open. We have evidence-based discussions about the benefits of new therapies for patients and their families, and how we can align our spending to make sure we get the most health we can out of the dollars we spend.

 

As we reflect on America’s past achievements and look to the challenges and opportunities facing us in the future, we can all commit to doing more now to make sure the latest innovations are reaching patients. Join us as we ensure fair pricing is met with fair access — leading to a more affordable health care system for us all. 

Let's see what happened this week...

 

ICER in the News

 

The obesity curve finally bent. Now comes the hard part.

The Boston Globe

Ashish K. Jha, cofounder and CEO of BioRadar USA and a senior fellow at Harvard’s Belfer Center, recently penned an op-ed about the obstacles to GLP-1 obesity medications. His piece mentioned ICER:

 

“These drugs are not merely cosmetic. For many patients, especially those with obesity and diabetes or heart disease, they prevent heart attacks, strokes, and kidney failure. Despite their high costs, they are a great value using the same standards used for other treatments. The independent Institute for Clinical and Economic Review found that, at estimated net prices, GLP-1 drugs were highly cost effective by commonly used thresholds… For context, Medicare has paid for end-stage kidney disease treatment, including dialysis and transplantation, since 1972, and these treatments cost nearly twice as much as GLP-1s for each additional life year saved. Dialysis is expensive but life-sustaining and rightly covered by Medicare. Obesity drugs should be covered by health insurance too.”


In the past year, ICER published two reports in the obesity space: 1) a White Paper on strategies to ensure affordable access for obesity medications and 2) a review on Wegovy (semaglutide) and Zepbound (tirzepatide) for obesity management, which found both therapies are highly cost-effective.

 
Pharmaceutical News

MUST READS


America’s small businesses are giving up on health insurance

STAT

STAT’s Bob Herman looked into how the current health care affordability crisis is affecting small businesses:

 

“Small business owners and workers feel as though most, if not all, of their options are unaffordable, especially if they have plans with high out-of-pocket costs. Rising premiums — driven by high prices for hospitals, doctors, and prescription drugs and more intensive care — are eating into bottom lines and paychecks. Desperate companies are getting rid of traditional health benefits at an unprecedented pace. This shift is fraying the uniquely American expectation that jobs come with protection for injuries and illnesses — an expectation that is the product of World War II wage controls, industry opposition to government health care, and the biggest break in the tax code.”

Copay Assistance Is Meant To Defray Patient Drug Costs. Some Insurers Keep It Instead.

KFF Health News

Several commercial health insurers now use what are called copay accumulator programs to keep funds that are meant to defray patients’ out-of-pocket costs for expensive specialty drugs. The result is that patients must pay more for access to medications. Over the past decade, more insurers have adopted such strategies to reduce their prescription drug costs, according to Avalere Health, a consulting company.

 

Patients who rely on copay assistance from drugmakers are typically heavy users of healthcare for whom delays in treatment or worsening conditions can lead to higher costs, according to patient advocates.

GOP lawmakers push Trump’s FDA to make sure clinical trials are diverse

STAT

Days after Trump took office, the Health and Human Services Department began purging all references to diversity, equity, and inclusion (DEI) from the websites of its agencies. Those efforts were supposed to target DEI initiatives focused on hiring practices, communications, and social issues. But supporters of clinical trial diversity say the policy has nothing to do with DEI in that sense. Instead, it aims to ensure that clinical trials enroll people who are similar to the patients who would use the drugs and medical devices being tested.

 

Congressional Republicans seem to agree. Last month, the Republican-controlled House passed a bill, mostly along party lines, to fund the Food and Drug Administration. It was accompanied by a report that, while not legally binding, tells agency officials what congressional appropriators expected of them. A section of that bill deals with trial diversity.

 

A couple of years ago, ICER-developed a Clinical Trial Diversity Rating (CDR) tool for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall rating. Groups such as Health Technology Assessment bodies, clinical trial regulators, policymakers, journal editors, and individual researchers can use this tool to examine, monitor, and improve diversity in clinical trials.

Obamacare premiums set for another double-digit jump

Axios

The cost of Obamacare coverage is due to rise by a median of 14% next year, according to a new analysis, marking further turmoil for the law's marketplaces. It would mark the second straight year of double-digit premium increases in the individual market. Customers could be on the hook for thousands of more dollars in costs, worsening the health affordability crisis.

These Medicare beneficiaries thought their drug plan was free. Then they lost it

KFF Health News

Thousands of Medicare beneficiaries on Wellcare's Value Script drug plan will likely go without prescription drug coverage for the rest of the year. Many did not receive any warning from their Medicare prescription drug plan that their $0 monthly premium had increased, and Wellcare cancelled coverage after several months of unpaid premiums.

OTHER HEADLINES

 

Join ICER!

 

Want to work for a fast-paced, mission-driven organization? Look no further! ICER is looking to expand our team:



 

Key Upcoming Dates

 
  • 7/27: Parkinson's Disease — Draft Evidence Report
  • 7/28: Covid-19 — Final Evidence Report
  • 8/12: Hypertension — Draft Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email